Jacob Pacifico1, Milou A J Geerlings2, Esmee M Reijnierse1, Christina Phassouliotis1, Wen Kwang Lim1, Andrea B Maier3. 1. Department of Medicine and Aged Care, @AgeMelbourne, The Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia. 2. Department of Clinical Physical Therapy, VieCuri Medical Center, Venlo, the Netherlands; Department of Human Movement Sciences, @AgeAmsterdam, Faculty of Behavioural and Movement Sciences, Amsterdam Movement Sciences, Vrije Universiteit, Amsterdam, the Netherlands. 3. Department of Medicine and Aged Care, @AgeMelbourne, The Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia; Department of Human Movement Sciences, @AgeAmsterdam, Faculty of Behavioural and Movement Sciences, Amsterdam Movement Sciences, Vrije Universiteit, Amsterdam, the Netherlands. Electronic address: andrea.maier@unimelb.edu.au.
Abstract
BACKGROUND: Sarcopenia shares risk factors with various other age-related diseases. This meta-analysis aimed to determine the prevalence of sarcopenia as a comorbid disease. METHODS: Medline, EMBASE and Cochrane databases were searched for articles from inception to 8th June 2018, reporting the prevalence of sarcopenia in individuals with a diagnosis of cardiovascular disease (CVD), dementia, diabetes mellitus or respiratory disease and, if applicable their controls. No exclusion criteria were applied with regards to definition of sarcopenia, individuals' age, study design and setting. Meta-analyses were stratified by disease, definition of sarcopenia and continent. RESULTS: The 63 included articles described 17,206 diseased individuals (mean age: 65.3 ± 1.6 years, 49.9% females) and 22,375 non-diseased controls (mean age: 54.6 ± 16.2 years, 53.8% females). The prevalence of sarcopenia in individuals with CVD was 31.4% (95% CI: 22.4-42.1%), no controls were available. The prevalence of sarcopenia was 26.4% (95% CI: 13.6-44.8%) in individuals with dementia compared to 8.3% (95% CI: 2.8-21.9%) in their controls; 31.1% (95% CI: 19.8-45.2%) in individuals with diabetes mellitus compared to 16.2% (95% CI: 9.5-26.2%) in controls; and 26.8% (95% CI: 17.8-38.1%) in individuals with respiratory diseases compared to 13.3% (95% CI: 8.3-20.7%) in controls. CONCLUSIONS: Sarcopenia is highly prevalent in individuals with CVD, dementia, diabetes mellitus and respiratory disease.
BACKGROUND:Sarcopenia shares risk factors with various other age-related diseases. This meta-analysis aimed to determine the prevalence of sarcopenia as a comorbid disease. METHODS: Medline, EMBASE and Cochrane databases were searched for articles from inception to 8th June 2018, reporting the prevalence of sarcopenia in individuals with a diagnosis of cardiovascular disease (CVD), dementia, diabetes mellitus or respiratory disease and, if applicable their controls. No exclusion criteria were applied with regards to definition of sarcopenia, individuals' age, study design and setting. Meta-analyses were stratified by disease, definition of sarcopenia and continent. RESULTS: The 63 included articles described 17,206 diseased individuals (mean age: 65.3 ± 1.6 years, 49.9% females) and 22,375 non-diseased controls (mean age: 54.6 ± 16.2 years, 53.8% females). The prevalence of sarcopenia in individuals with CVD was 31.4% (95% CI: 22.4-42.1%), no controls were available. The prevalence of sarcopenia was 26.4% (95% CI: 13.6-44.8%) in individuals with dementia compared to 8.3% (95% CI: 2.8-21.9%) in their controls; 31.1% (95% CI: 19.8-45.2%) in individuals with diabetes mellitus compared to 16.2% (95% CI: 9.5-26.2%) in controls; and 26.8% (95% CI: 17.8-38.1%) in individuals with respiratory diseases compared to 13.3% (95% CI: 8.3-20.7%) in controls. CONCLUSIONS:Sarcopenia is highly prevalent in individuals with CVD, dementia, diabetes mellitus and respiratory disease.
Authors: Hugo Falqueto; Jorge L R Júnior; Mauro N O Silvério; Juliano C H Farias; Brad J Schoenfeld; Leandro H Manfredi Journal: Rev Endocr Metab Disord Date: 2021-03-30 Impact factor: 6.514
Authors: Malou A H Nuijten; Thijs M H Eijsvogels; Valerie M Monpellier; Ignace M C Janssen; Eric J Hazebroek; Maria T E Hopman Journal: Obes Rev Date: 2021-10-19 Impact factor: 10.867
Authors: Yuxiao Guo; Jessica Piasecki; Agnieszka Swiecicka; Alex Ireland; Bethan E Phillips; Philip J Atherton; Daniel Stashuk; Martin K Rutter; Jamie S McPhee; Mathew Piasecki Journal: Geroscience Date: 2021-12-03 Impact factor: 7.581